Enfusion Results Presentation Deck

Reconciliations To Non-GAAP Financial Measures The following table reconciles gross profit to adjusted gross profit: ($ in thousands) GAAP Gross profit Add back stock based compensation expense Adjusted Gross profit Adjusted Gross Margin ($ in thousands) Net income (loss) Interest expense Income taxes The following table reconciles net income to Adjusted EBITDA: Depreciation and amortization EBITDA Adjustments: Stock-based compensation expense Loss on debt extinguishment Taxpayment on stock-based compensation Adjusted EBITDA Adjusted EBITDA margin *:enfusion $ $ December 31, 2021 21,689 377 22,066 69.3% December 31, 2021 (293,894) 307 (125) 1,316 (292,396) 289,803 1,215 4,570 3,192 10.0% March 30, 2022 23,158 354 23,512 68.9% March 30, 2022 (12,524) 6 150 1,340 (11,028) 12,432 434 1,838 5.4% Three Months Ended June 30, 2022 25,693 341 26,034 71.2% Three Months Ended June 30, 2022 (4,125) 1 219 1,615 (2,290) 7,523 50 5,283 14.5% September 30, 2022 27,177 406 27,583 70.5% September 30, 2022 2,598 4 287 1,699 4,588 833 14 5,435 13.9% December 31, 2022 27,221 321 27,542 68.0% December 31, 2022 788 (424) 418 1,690 2,472 4,205 87 6,764 16.7% PROPRIETARY AND CONFIDENTIAL Ⓒ2023 ENFUSION. ALL RIGHTS RESERVED. 18

View entire presentation